特發性肺纖維化預后的影響因素_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

歐陽小荔 ¹ ,  彭紅 ^1,2

1. ;
2. ;

Corresponding?author：

彭紅, Email: penghong66@csu.edu.cn

Keywords：

DOI：

10.7507/1671-6205.202007054

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 歐陽小荔, 彭紅. 特發性肺纖維化預后的影響因素. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(11): 824-830. doi: 10.7507/1671-6205.202007054 Copy

1.	Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med, 2018, 378(19): 1811-1823.
2.	Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med, 2014, 2(7): 566-572.
3.	Leuschner G, Klotsche J, Kreuter M, et al. Idiopathic pulmonary fibrosis in elderly patients: analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne), 2020, 7: 601279.
4.	Du Bois R, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2011, 184(4): 459-466.
5.	Caminati A, Madotto F, Conti S, et al. The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities. Intern Emerg Med, 2021, 16(7): 1793-1802.
6.	Zaman T, Moua T, Vittinghoff E, et al. Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study. Chest, 2020, 158(1): 245-251.
7.	Jeganathan N, Smith R, Sathananthan M. Mortality trends of idiopathic pulmonary fibrosis in the United States from 2004 through 2017. Chest, 2021, 159(1): 228-238.
8.	Kalafatis D, Gao J, Pesonen I, et al. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden. BMC Pulm Med, 2019, 19(1): 222.
9.	Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition, 2019, 62: 115-121.
10.	Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration, 2018, 96(4): 338-347.
11.	Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res, 2020, 21(1): 312.
12.	Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest, 2007, 131(5): 1448-1453.
13.	Kulkarni T, Yuan K, Tran-Nguyen T, et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One, 2019, 14(10): e0221905.
14.	Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 480-485.
15.	Bellou V, Belbasis L, Evangelou E. Tobacco smoking and risk for pulmonary fibrosis: a prospective cohort study from the UK Biobank. Chest, 2021, 160(3): 983-993.
16.	Antoniou K, Hansell D, Rubens M, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med, 2008, 177(2): 190-194.
17.	K?rkk?inen M, Kettunen HP, Nurmi H, et al. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 160.
18.	Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J, 2017, 49(2): 1601592.
19.	Zubairi A, Ahmad H, Hassan M, et al. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: an experience from a tertiary care center in Pakistan. Clin Respir J, 2018, 12(3): 1191-1196.
20.	Agarwala P, Salzman S. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest, 2020, 157(3): 603-611.
21.	Du Bois R, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med, 2011, 183(9): 1231-1237.
22.	Ochman M, Urlik M, Tatoj Z, et al. Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis - single-centre experience. Arch Med Sci, 2020, 16(3): 621-626.
23.	Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med, 2009, 103(1): 117-123.
24.	Paterniti M, Bi Y, Reki? D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc, 2017, 14(9): 1395-1402.
25.	Snyder L, Neely M, Hellkamp A, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res, 2019, 20(1): 105.
26.	Guo L, Yang Y, Liu F, et al. Clinical research on prognostic evaluation of subjects with ipf by peripheral blood biomarkers, quantitative imaging characteristics and pulmonary function parameters. Arch Bronconeumol, 2020, 56(6): 365-372.
27.	Huang T, Kuo C, Chen C, et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm Med, 2021, 21(1): 165.
28.	Aloisio E, Braga F, Puricelli C, et al. Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Chem Lab Med, 2021, 59(8): 1400-1408.
29.	Ishii H, Kushima H, Kinoshita Y, et al. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin Respir J, 2018, 12(9): 2411-2418.
30.	Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ open research, 2017, 3(3): 00019-02016.
31.	Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 486-493.
32.	Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med, 2017, 5(12): 946-955.
33.	Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest, 2013, 143(5): 1422-1429.
34.	Ikeda K, Chiba H, Nishikiori H, et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res, 2020, 21(1): 316.
35.	Ley B, Ryerson C, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med, 2012, 156(10): 684-691.
36.	Tran T, ?terclová M, Mogulkoc N, et al. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respir Res, 2020, 21(1): 11.
37.	Wells A, Desai S, Rubens M, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med, 2003, 167(7): 962-969.
38.	Jo HE, Glaspole I, Moodley Y, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med, 2018, 18(1): 19.
39.	Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
40.	特發性肺纖維化急性加重診斷和治療中國專家共識. 中華醫學雜志, 2019(26): 2014-2023.
41.	Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med, 2014, 190(7): 773-779.
42.	Zhuang Y, Zhou Y, Qiu X, et al. Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep, 2020, 10(1): 10742.
43.	Collard HR, Richeldi L, Kim DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J, 2017, 49(5): 1601339.
44.	Dotan Y, Vaidy A, Shapiro W, et al. Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome. Chest, 2018, 154(4): 818-826.
45.	Prior T, Hoyer N, Hilberg O, et al. Clusters of comorbidities in idiopathic pulmonary fibrosis. Respir Med, 2021, 185: 106490.
46.	King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med, 2017, 5(1): 72-84.
47.	Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J, 2017, 50(1): 1700379.
48.	Jiang C, Fu Q, Zheng C. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis, 2019, 13: 1753466619888119.
49.	Lai RS, Chen CF, Chu KA, et al. The effect of emphysema on survival in patients with idiopathic pulmonary fibrosis: a retrospective study in Taiwan. J Chin Med Assoc, 2019, 82(12): 922-928.
50.	Kohashi Y, Arai T, Sugimoto C, et al. Clinical impact of emphysema evaluated by high-resolution computed tomography on idiopathic pulmonary fibrosis diagnosed by surgical lung biopsy. Respiration, 2016, 92(4): 220-228.
51.	Portillo K, Perez-Rodas N, García-Olivé I, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis. A descriptive study in a Spanish Series. Arch Bronconeumol, 2017, 53(6): 304-310.
52.	Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev, 2019, 28(153): 190044.
53.	Rajagopal K, Bryant A, Sahay S, et al. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. Br J Pharmacol, 2021, 178(1): 172-186.
54.	Raghu G, Nathan S, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J, 2015, 46(5): 1370-1377.
55.	Judge E, Fabre A, Adamali H, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J, 2012, 40(1): 93-100.
56.	Teramachi R, Taniguchi H, Kondoh Y, et al. Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction. Respirology, 2017, 22(5): 986-990.
57.	Tzouvelekis A, Karampitsakos T, Gomatou G, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. A retrospective multicenter study in Greece. Pulm Pharmacol Ther, 2020, 60: 101880.
58.	Lee H, Cho J, Kwak N, et al. Prognostic impact of malignant diseases in idiopathic pulmonary fibrosis. Sci Rep, 2020, 10(1): 18260.
59.	Yoon J, Nouraie M, Chen X, et al. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data. Respir Res, 2018, 19(1): 195.
60.	Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther, 2017, 45: 1-10.
61.	Song M, Kim S, Park M, et al. A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis. Sci Rep, 2021, 11(1): 2596.
62.	Türkkan G, Willems Y, Hendriks LEL, et al. Idiopathic pulmonary fibrosis: current knowledge, future perspectives and its importance in radiation oncology. Radiother Oncol, 2021, 155: 269-277.
63.	Kanaji N, Shimizu J, Sakai K, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis, 2020, 14: 1753466620963866.
64.	Kanayama M, Mori M, Matsumiya H, et al. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surg Today, 2020, 50(5): 469-474.
65.	Papadogiannis G, Bouloukaki I, Mermigkis C, et al. Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment. J Clin Sleep Med, 2021, 17(3): 533-544.
66.	Bosi M, Milioli G, Fanfulla F, et al. OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in IPF. Lung, 2017, 195(5): 643-651.
67.	Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther, 2021, 38(2): 854-867.
68.	Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J, 2021, 57(2): 2002718.
69.	Kang J, Han M, Song J. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep, 2020, 10(1): 15620.
70.	Riddell P, Kleinerova J, Eaton D, et al. Meaningful survival benefit for single lung transplantation in idiopathic pulmonary fibrosis patients over 65 years of age. Eur Respir J, 2020, 56(1): 1902413.
71.	Ranganath NK, Malas J, Phillips KG, et al. Single and double lung transplantation have equivalent survival for idiopathic pulmonary fibrosis. Ann Thorac Surg, 2020, 109(1): 211-217.
72.	Li D, Liu Y, Wang B. Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS One, 2020, 15(5): e0233732.

1. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med, 2018, 378(19): 1811-1823.
2. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med, 2014, 2(7): 566-572.
3. Leuschner G, Klotsche J, Kreuter M, et al. Idiopathic pulmonary fibrosis in elderly patients: analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne), 2020, 7: 601279.
4. Du Bois R, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2011, 184(4): 459-466.
5. Caminati A, Madotto F, Conti S, et al. The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities. Intern Emerg Med, 2021, 16(7): 1793-1802.
6. Zaman T, Moua T, Vittinghoff E, et al. Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study. Chest, 2020, 158(1): 245-251.
7. Jeganathan N, Smith R, Sathananthan M. Mortality trends of idiopathic pulmonary fibrosis in the United States from 2004 through 2017. Chest, 2021, 159(1): 228-238.
8. Kalafatis D, Gao J, Pesonen I, et al. Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden. BMC Pulm Med, 2019, 19(1): 222.
9. Jouneau S, Kerjouan M, Rousseau C, et al. What are the best indicators to assess malnutrition in idiopathic pulmonary fibrosis patients? A cross-sectional study in a referral center. Nutrition, 2019, 62: 115-121.
10. Nakatsuka Y, Handa T, Kokosi M, et al. The clinical significance of body weight loss in idiopathic pulmonary fibrosis patients. Respiration, 2018, 96(4): 338-347.
11. Jouneau S, Crestani B, Thibault R, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res, 2020, 21(1): 312.
12. Alakhras M, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest, 2007, 131(5): 1448-1453.
13. Kulkarni T, Yuan K, Tran-Nguyen T, et al. Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients. PLoS One, 2019, 14(10): e0221905.
14. Nishiyama O, Yamazaki R, Sano H, et al. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 480-485.
15. Bellou V, Belbasis L, Evangelou E. Tobacco smoking and risk for pulmonary fibrosis: a prospective cohort study from the UK Biobank. Chest, 2021, 160(3): 983-993.
16. Antoniou K, Hansell D, Rubens M, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med, 2008, 177(2): 190-194.
17. K?rkk?inen M, Kettunen HP, Nurmi H, et al. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res, 2017, 18(1): 160.
18. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J, 2017, 49(2): 1601592.
19. Zubairi A, Ahmad H, Hassan M, et al. Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: an experience from a tertiary care center in Pakistan. Clin Respir J, 2018, 12(3): 1191-1196.
20. Agarwala P, Salzman S. Six-minute walk test: clinical role, technique, coding, and reimbursement. Chest, 2020, 157(3): 603-611.
21. Du Bois R, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med, 2011, 183(9): 1231-1237.
22. Ochman M, Urlik M, Tatoj Z, et al. Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis - single-centre experience. Arch Med Sci, 2020, 16(3): 621-626.
23. Caminati A, Bianchi A, Cassandro R, et al. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med, 2009, 103(1): 117-123.
24. Paterniti M, Bi Y, Reki? D, et al. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc, 2017, 14(9): 1395-1402.
25. Snyder L, Neely M, Hellkamp A, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res, 2019, 20(1): 105.
26. Guo L, Yang Y, Liu F, et al. Clinical research on prognostic evaluation of subjects with ipf by peripheral blood biomarkers, quantitative imaging characteristics and pulmonary function parameters. Arch Bronconeumol, 2020, 56(6): 365-372.
27. Huang T, Kuo C, Chen C, et al. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulm Med, 2021, 21(1): 165.
28. Aloisio E, Braga F, Puricelli C, et al. Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Chem Lab Med, 2021, 59(8): 1400-1408.
29. Ishii H, Kushima H, Kinoshita Y, et al. The serum KL-6 levels in untreated idiopathic pulmonary fibrosis can naturally decline in association with disease progression. Clin Respir J, 2018, 12(9): 2411-2418.
30. Sokai A, Tanizawa K, Handa T, et al. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ open research, 2017, 3(3): 00019-02016.
31. Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology, 2017, 22(3): 486-493.
32. Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med, 2017, 5(12): 946-955.
33. Song JW, Do KH, Jang SJ, et al. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest, 2013, 143(5): 1422-1429.
34. Ikeda K, Chiba H, Nishikiori H, et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res, 2020, 21(1): 316.
35. Ley B, Ryerson C, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med, 2012, 156(10): 684-691.
36. Tran T, ?terclová M, Mogulkoc N, et al. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respir Res, 2020, 21(1): 11.
37. Wells A, Desai S, Rubens M, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med, 2003, 167(7): 962-969.
38. Jo HE, Glaspole I, Moodley Y, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med, 2018, 18(1): 19.
39. Gao J, Kalafatis D, Carlson L, et al. Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respir Res, 2021, 22(1): 40.
40. 特發性肺纖維化急性加重診斷和治療中國專家共識. 中華醫學雜志, 2019(26): 2014-2023.
41. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med, 2014, 190(7): 773-779.
42. Zhuang Y, Zhou Y, Qiu X, et al. Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep, 2020, 10(1): 10742.
43. Collard HR, Richeldi L, Kim DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J, 2017, 49(5): 1601339.
44. Dotan Y, Vaidy A, Shapiro W, et al. Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome. Chest, 2018, 154(4): 818-826.
45. Prior T, Hoyer N, Hilberg O, et al. Clusters of comorbidities in idiopathic pulmonary fibrosis. Respir Med, 2021, 185: 106490.
46. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med, 2017, 5(1): 72-84.
47. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. Eur Respir J, 2017, 50(1): 1700379.
48. Jiang C, Fu Q, Zheng C. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis, 2019, 13: 1753466619888119.
49. Lai RS, Chen CF, Chu KA, et al. The effect of emphysema on survival in patients with idiopathic pulmonary fibrosis: a retrospective study in Taiwan. J Chin Med Assoc, 2019, 82(12): 922-928.
50. Kohashi Y, Arai T, Sugimoto C, et al. Clinical impact of emphysema evaluated by high-resolution computed tomography on idiopathic pulmonary fibrosis diagnosed by surgical lung biopsy. Respiration, 2016, 92(4): 220-228.
51. Portillo K, Perez-Rodas N, García-Olivé I, et al. Lung cancer in patients with combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis. A descriptive study in a Spanish Series. Arch Bronconeumol, 2017, 53(6): 304-310.
52. Caminati A, Lonati C, Cassandro R, et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev, 2019, 28(153): 190044.
53. Rajagopal K, Bryant A, Sahay S, et al. Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. Br J Pharmacol, 2021, 178(1): 172-186.
54. Raghu G, Nathan S, Behr J, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J, 2015, 46(5): 1370-1377.
55. Judge E, Fabre A, Adamali H, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J, 2012, 40(1): 93-100.
56. Teramachi R, Taniguchi H, Kondoh Y, et al. Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction. Respirology, 2017, 22(5): 986-990.
57. Tzouvelekis A, Karampitsakos T, Gomatou G, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. A retrospective multicenter study in Greece. Pulm Pharmacol Ther, 2020, 60: 101880.
58. Lee H, Cho J, Kwak N, et al. Prognostic impact of malignant diseases in idiopathic pulmonary fibrosis. Sci Rep, 2020, 10(1): 18260.
59. Yoon J, Nouraie M, Chen X, et al. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease - analysis of institutional and population data. Respir Res, 2018, 19(1): 195.
60. Karampitsakos T, Tzilas V, Tringidou R, et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm Pharmacol Ther, 2017, 45: 1-10.
61. Song M, Kim S, Park M, et al. A nationwide population-based study of incidence and mortality of lung cancer in idiopathic pulmonary fibrosis. Sci Rep, 2021, 11(1): 2596.
62. Türkkan G, Willems Y, Hendriks LEL, et al. Idiopathic pulmonary fibrosis: current knowledge, future perspectives and its importance in radiation oncology. Radiother Oncol, 2021, 155: 269-277.
63. Kanaji N, Shimizu J, Sakai K, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis, 2020, 14: 1753466620963866.
64. Kanayama M, Mori M, Matsumiya H, et al. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surg Today, 2020, 50(5): 469-474.
65. Papadogiannis G, Bouloukaki I, Mermigkis C, et al. Patients with idiopathic pulmonary fibrosis with and without obstructive sleep apnea: differences in clinical characteristics, clinical outcomes, and the effect of PAP treatment. J Clin Sleep Med, 2021, 17(3): 533-544.
66. Bosi M, Milioli G, Fanfulla F, et al. OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in IPF. Lung, 2017, 195(5): 643-651.
67. Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther, 2021, 38(2): 854-867.
68. Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J, 2021, 57(2): 2002718.
69. Kang J, Han M, Song J. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep, 2020, 10(1): 15620.
70. Riddell P, Kleinerova J, Eaton D, et al. Meaningful survival benefit for single lung transplantation in idiopathic pulmonary fibrosis patients over 65 years of age. Eur Respir J, 2020, 56(1): 1902413.
71. Ranganath NK, Malas J, Phillips KG, et al. Single and double lung transplantation have equivalent survival for idiopathic pulmonary fibrosis. Ann Thorac Surg, 2020, 109(1): 211-217.
72. Li D, Liu Y, Wang B. Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS One, 2020, 15(5): e0233732.

Previous Article
靶肺去神經療法在慢性阻塞性肺疾病中的應用進展
Next Article
重癥加強治療病房有創機械通氣患者早期肺康復研究進展

Chinese Journal of Respiratory and Critical Care Medicine

特發性肺纖維化預后的影響因素

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content